The gene therapy developer's latest round featured a $75m investment from Novartis and was closed as it withdrew its IPO application.

Pharmaceutical firm Novartis invested $75m in US-based gene therapy developer Poseida Therapeutics yesterday to lead its $142m series C round.

Life sciences investment firm Malin also took part in the round, as did Aisling Capital, Pentwater Capital, Perceptive Advisors, Longitude Capital, Vivo Capital and Tavistock Group’s Boxer Capital unit.

Poseida Therapeutics is using gene engineering technologies to develop treatments for orphan genetic diseases, haematological malignancies and solid tumours.

The company’s lead drug candidate, P-BCMA-101, is in a phase 1 trial…